Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER-2 Positive Esophageal Cancer”

49 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 49 results

Large-scale testing (Phase 3)Active Not RecruitingNCT04704934
What this trial is testing

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Who this might be right for
Gastric Cancer, AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Daiichi Sankyo 490
Testing effectiveness (Phase 2)Ended earlyNCT00447226
What this trial is testing

Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists

Who this might be right for
Cancer
GlaxoSmithKline 32
Testing effectiveness (Phase 2)Looking for participantsNCT05965479
What this trial is testing

Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer

Who this might be right for
Gastrooesophageal Cancer
University of Southampton 25
Testing effectiveness (Phase 2)Study completedNCT02954536
What this trial is testing

Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer

Who this might be right for
Esophageal CancerGastric Cancer
Memorial Sloan Kettering Cancer Center 37
Early research (Phase 1)Looking for participantsNCT06500052
What this trial is testing

BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors

Who this might be right for
Esophageal CancerGastric CancerPancreatic Cancer+2 more
Sichuan Baili Pharmaceutical Co., Ltd. 20
Large-scale testing (Phase 3)Ended earlyNCT01450696
What this trial is testing

Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Who this might be right for
Gastric Cancer
Hoffmann-La Roche 296
Large-scale testing (Phase 3)Study completedNCT00680901
What this trial is testing

LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

Who this might be right for
Neoplasms, Gastrointestinal Tract
Novartis Pharmaceuticals 545
Testing effectiveness (Phase 2)Study completedNCT03409848
What this trial is testing

Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma

Who this might be right for
Gastric CancerEsophageal CancerAdenocarcinoma Gastric+3 more
AIO-Studien-gGmbH 97
Testing effectiveness (Phase 2)Study completedNCT01522768
What this trial is testing

Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer

Who this might be right for
Esophageal CancerGastric Cancer
Memorial Sloan Kettering Cancer Center 42
Large-scale testing (Phase 3)Looking for participantsNCT05427383
What this trial is testing

KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy

Who this might be right for
Stomach Cancer
Shanghai JMT-Bio Inc. 286
Testing effectiveness (Phase 2)UnknownNCT05170256
What this trial is testing

Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients

Who this might be right for
Esophageal Squamous Cell CarcinomaHER-2 Protein OverexpressionHER-2 Gene Amplification
Morten Mau-Sørensen 24
Testing effectiveness (Phase 2)Ended earlyNCT04467515
What this trial is testing

Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer

Who this might be right for
Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment
Precirix 13
Not applicableNot Yet RecruitingNCT07191405
What this trial is testing

Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors

Who this might be right for
ImmunotherapyChemotherapy
Second Affiliated Hospital, Zhejiang University, School of Medicine 156
Testing effectiveness (Phase 2)Active Not RecruitingNCT04802876
What this trial is testing

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors

Who this might be right for
MSI-H Colorectal CancerMelanomaAnal Carcinoma+28 more
SOLTI Breast Cancer Research Group 184
Testing effectiveness (Phase 2)Study completedNCT01364493
What this trial is testing

Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer

Who this might be right for
Gastric Cancer
Peking University 51
Large-scale testing (Phase 3)Study completedNCT04499924
What this trial is testing

Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaEsophageal Adenocarcinoma
Seagen Inc. 17
Early research (Phase 1)Ended earlyNCT03680560
What this trial is testing

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

Who this might be right for
Solid TumorHER-2 Protein Overexpression
Cogent Biosciences, Inc. 6
Early research (Phase 1)Looking for participantsNCT06414733
What this trial is testing

HER-2 B Cell Peptide Vaccine

Who this might be right for
Metastatic Breast CancerHER2-positive Breast CancerEGFR Overexpression+2 more
Pravin T.P Kaumaya 42
Testing effectiveness (Phase 2)Active Not RecruitingNCT05480384
What this trial is testing

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

Who this might be right for
Esophageal AdenocarcinomaEsophageal CancerHER-2 Protein Overexpression+1 more
Brown University 1
Large-scale testing (Phase 3)Active Not RecruitingNCT05152147
What this trial is testing

Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Who this might be right for
Gastric NeoplasmsGastroesophageal AdenocarcinomaEsophageal Adenocarcinoma
Jazz Pharmaceuticals 920
Next Page